Marcia N Gordon

List of Publications by Year
in descending order

106	19,581	46636 47	28046 106
papers	citations	h-index	g-index

133	133	133	22747
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Induction of tauopathy in a mouse model of amyloidosis using intravenous administration of adenoâ€associated virus vectors expressing human P301L tau. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2024, 10, .	3.9	0
2	Neural atrophy produced by AAV tau injections into hippocampus and anterior cortex of middle-aged mice. Neurobiology of Aging, 2023, 124, 39-50.	3.2	2
3	Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 360-376.	0.7	56
4	Accumulation of C-terminal cleaved tau is distinctly associated with cognitive deficits, synaptic plasticity impairment, and neurodegeneration in aged mice. GeroScience, 2022, 44, 173-194.	4.7	9
5	Impact of COVIDâ€19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research. Alzheimer's and Dementia, 2022, 18, 1038-1046.	0.7	40
6	Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice. International Journal of Molecular Sciences, 2022, 23, 2757.	4.2	10
7	The Memory Benefit to Aged APP/PS1 Mice from Long-Term Intranasal Treatment of Low-Dose THC. International Journal of Molecular Sciences, 2022, 23, 4253.	4.2	4
8	Myeloid Arginase 1 Insufficiency Exacerbates Amyloid-Î² Associated Neurodegenerative Pathways and Glial Signatures in a Mouse Model of Alzheimerâ€™s Disease: A Targeted Transcriptome Analysis. Frontiers in Immunology, 2021, 12, 628156.	4.9	10
9	Toward Development of Neuron Specific Transduction After Systemic Delivery of Viral Vectors. Frontiers in Neurology, 2021, 12, 685802.	2.5	17
10	An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-Î²1. Journal of Alzheimer's Disease, 2020, 77, 1639-1653.	2.7	9
11	CCL2 Overexpression in the Brain Promotes Glial Activation and Accelerates Tau Pathology in a Mouse Model of Tauopathy. Frontiers in Immunology, 2020, 11, 997.	4.9	61
12	Arginase 1 Insufficiency Precipitates Amyloid-Î² Deposition and Hastens Behavioral Impairment in a Mouse Model of Amyloidosis. Frontiers in Immunology, 2020, 11, 582998.	4.9	18
13	Spermidine/spermine-N1-acetyltransferase ablation impacts tauopathy-induced polyamine stress response. Alzheimer's Research and Therapy, 2019, 11, 58.	6.4	33
14	CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model. Journal of NeuroImmune Pharmacology, 2019, 14, 312-325.	4.0	26
15	P3â€176: AGE AS A PREDICTOR OF DIFFERENT PHYSIOLOGICAL FORMS OF TAU. Alzheimer's and Dementia, 2018, 14, P1135.	0.7	0
16	Disruption of normal circadian clock function in a mouse model of tauopathy. Experimental Neurology, 2017, 294, 58-67.	4.1	72
17	Unbiased estimation of cell number using the automatic optical fractionator. Journal of Chemical Neuroanatomy, 2017, 80, A1-A8.	2.2	27
18	Oligomeric tau-targeted immunotherapy in Tg4510 mice. Alzheimer's Research and Therapy, 2017, 9, 46.	6.4	14

#	Article	IF	Citations
19	Metabolic changes over the course of aging in a mouse model ofÂtauÂdeposition. Neurobiology of Aging, 2016, 44, 62-73.	3.2	33
20	Adeno associated viral-mediated intraosseous labeling of bone marrow derived cells for CNS tracking. Journal of Immunological Methods, 2016, 432, 51-56.	1.4	6
21	Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimerâ€™s Disease and Other Tauopathies. Journal of NeuroImmune Pharmacology, 2016, 11, 9-25.	4.0	45
22	Convection Enhanced Delivery of Recombinant Adeno-associated Virus into the Mouse Brain. Methods in Molecular Biology, 2016, 1382, 285-295.	0.0	6
23	P3-007: Characterization of full length and c-terminal truncated tau pathological progression with age in wild type mice. Alzheimer's and Dementia, 2015, 11, P621-P622.	0.7	0
24	Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy. Journal of Neuroscience, 2015, 35, 14842-14860.	3.8	39
25	Dendritic and Langerhans cells respond to AÎ² peptides differently: implication for AD immunotherapy. Oncotarget, 2015, 6, 35443-35457.	2.1	4
26	Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. Journal of Neuroinflammation, 2014, 11, 152.	7.4	36
27	Effects of Repetitive Exposure to Anesthetics and Analgesics in the Tg2576 Mouse Alzheimerâ€™s Model. Neurotoxicity Research, 2014, 26, 414-421.	2.7	17
28	Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. Behavioural Brain Research, 2014, 271, 79-88.	2.3	62
29	Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition. Alzheimer's Research and Therapy, 2014, 6, 12.	6.4	108
30	Intraventricular Human Immunoglobulin Distributes Extensively but Fails to Modify Amyloid in a Mouse Model of Amyloid Deposition. Current Alzheimer Research, 2014, 11, 664-671.	1.5	5
31	Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. Journal of Neuroinflammation, 2013, 10, 86.	7.4	81
32	Aging enhances classical activation but mitigates alternative activation in the central nervous system. Neurobiology of Aging, 2013, 34, 1610-1620.	3.2	107
33	Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiology of Aging, 2013, 34, 1540-1548.	3.2	90
34	Intracranial Injection of AAV Expressing NEP but Not IDE Reduces Amyloid Pathology in APP+PS1 Transgenic Mice. PLoS ONE, 2013, 8, e59626.	2.5	36
35	Ketogenic Diet Improves Motor Performance but Not Cognition in Two Mouse Models of Alzheimerâ€™s Pathology. PLoS ONE, 2013, 8, e75713.	2.5	119
36	Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-Î³. Apoptosis: an International Journal on Programmed Cell Death, 2012, 17, 691-701.	4.9	7

#	Article	IF	Citations
37	Chronological Age Impacts Immunotherapy and Monocyte Uptake Independent of Amyloid Load. Journal of NeuroImmune Pharmacology, 2012, 7, 202-214.	4.0	10
38	Diverse Inflammatory Responses in Transgenic Mouse Models of Alzheimer's Disease and the Effect of Immunotherapy on These Responses. ASN Neuro, 2011, 3, AN20110018.	3.0	40
39	Activation of matrix metalloproteinases following anti-AÎ² immunotherapy; implications for microhemorrhage occurrence. Journal of Neuroinflammation, 2011, 8, 115.	7.4	33
40	Virus-like Peptide Vaccines Against AÃŸ N-terminal or C-Terminal Domains Reduce Amyloid Deposition in APP Transgenic Mice without Addition of Adjuvant. Journal of NeuroImmune Pharmacology, 2010, 5, 133-142.	4.0	19
41	Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene product in the adult mouse brain. Journal of Neuroscience Methods, 2010, 194, 144-153.	2.6	66
42	Abnormal postâ€translational and extracellular processing of brevican in plaqueâ€bearing mice overâ€expressing APPsw. Journal of Neurochemistry, 2010, 113, 784-795.	4.0	33
43	Trafficking CD11b-Positive Blood Cells Deliver Therapeutic Genes to the Brain of Amyloid-Depositing Transgenic Mice. Journal of Neuroscience, 2010, 30, 9651-9658.	3.8	119
44	LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. Journal of Neuroinflammation, 2010, 7, 56.	7.4	241
45	Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice. Journal of Neuroscience, 2009, 29, 4964-4971.	3.8	30
46	Deglycosylated Anti-AÎ² Antibody Doseâ€“Response Effects on Pathology and Memory in APP Transgenic Mice. Journal of NeuroImmune Pharmacology, 2008, 3, 187-197.	4.0	23
47	Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Neurobiology of Aging, 2008, 29, 1512-1523.	3.2	33
48	Adeno-associated Viral (AAV) Serotype 5 Vector Mediated Gene Delivery of Endothelin-converting Enzyme Reduces AÎ² Deposits in APP + PS1 Transgenic Mice. Molecular Therapy, 2008, 16, 1580-1586.	8.1	64
49	Amyloid, hyperactivity, and metabolism: Theoretical comment on Vloeberghs et al. (2008).. Behavioral Neuroscience, 2008, 122, 730-732.	1.2	15
50	Apparent Behavioral Benefits of Tau Overexpression in P301L Tau Transgenic Mice. Journal of Alzheimer's Disease, 2008, 15, 605-614.	2.7	36
51	Contrasting In Vivo Effects of Two Peptide-Based Amyloid-Î² Protein Aggregation Inhibitors in a Transgenic Mouse Model of Amyloid Deposition. Cell Transplantation, 2008, 17, 397-408.	2.6	5
52	The H-2 receptor antagonist cimetidine blocks kainic acid toxicity in hippocampus as effectively as the NMDA receptor antagonist MK-801. Journal of Neuropathology and Experimental Neurology, 2007, 66, 420.	1.8	0
53	Organization and Function of the Central Nervous System. , 2007, , 1-8.		0
54	Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-AÎ² antibodies. BMC Neuroscience, 2007, 8, 22.	1.8	41

#	Article	IF	Citations
55	Up-regulation of Bcl-2 in APP transgenic mice is associated with neuroprotection. Neurobiology of Disease, 2007, 25, 179-188.	4.5	28
56	Microglial Activation is Required for AÎ² Clearance After Intracranial Injection of Lipopolysaccharide in APP Transgenic Mice. Journal of NeuroImmune Pharmacology, 2007, 2, 222-231.	4.0	140
57	The Hâ€2 Receptor Antagonist Cimetidine Blocks Kainic Acid Toxicity in Hippocampus as Effectively as the NMDA Receptor Antagonist MKâ€801. FASEB Journal, 2007, 21, A20.	0.5	0
58	Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. Journal of Neuroinflammation, 2006, 3, 11.	7.4	42
59	Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiology of Aging, 2006, 27, 1118-1128.	3.2	47
60	Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia, 2006, 53, 382-391.	5.3	107
61	Deglycosylated Anti-Amyloid-beta Antibodies Eliminate Cognitive Deficits and Reduce Parenchymal Amyloid with Minimal Vascular Consequences in Aged Amyloid Precursor Protein Transgenic Mice. Journal of Neuroscience, 2006, 26, 5340-5346.	3.8	157
62	Dysregulation of Na+/K+ ATPase by amyloid in APP+PS1 transgenic mice. BMC Neuroscience, 2005, 6, 7.	1.8	60
63	Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics. Journal of Neuropathology and Experimental Neurology, 2005, 64, 743-753.	1.8	166
64	Caloric restriction attenuates AÎ²-deposition in Alzheimer transgenic models. Neurobiology of Aging, 2005, 26, 995-1000.	3.2	313
65	Amyloid suppresses induction of genes critical for memory consolidation in APPâ€ƒ+â€ƒPS1 transgenic mice. Journal of Neurochemistry, 2004, 88, 434-442.	4.0	82
66	Biochemical and Histochemical Evidence of Nonspecific Binding of Î±7nAChR Antibodies to Mouse Brain Tissue. Journal of Histochemistry and Cytochemistry, 2004, 52, 1367-1375.	2.6	83
67	Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition. Journal of Neuroscience, 2004, 24, 6144-6151.	3.8	293
68	Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neuroscience, 2004, 5, 21.	1.8	47
69	Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magnetic Resonance in Medicine, 2004, 51, 452-457.	3.1	84
70	Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. Journal of Neuroinflammation, 2004, 1, 24.	7.4	348
71	Time-dependent reduction in AÎ² levels after intracranial LPS administration in APP transgenic mice. Experimental Neurology, 2004, 190, 245-253.	4.1	143
72	Microglial activation facilitates AÎ² plaque removal following intracranial anti-AÎ² antibody administration. Neurobiology of Disease, 2004, 15, 11-20.	4.5	190

#	Article	IF	Citations
73	Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochemical Research, 2003, 28, 83-93.	3.3	32
74	The Association of Microglial Activation and Amyloid Reduction in APP+PS1 Transgenic Mice. Current Medicinal Chemistry Immunology, Endocrine & Metabolic Agents, 2003, 3, 27-32.	0.2	0
75	Neuregulin-1 and ErbB4 Immunoreactivity Is Associated with Neuritic Plaques in Alzheimer Disease Brain and in a Transgenic Model of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2003, 62, 42-54.	1.8	111
76	Intracranially Administered Anti-ÎĺÎ² Antibodies Reduce Î²-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation. Journal of Neuroscience, 2003, 23, 3745-3751.	3.8	236
77	Selectively Reduced Expression of Synaptic Plasticity-Related Genes in Amyloid Precursor Protein + Presenilin-1 Transgenic Mice. Journal of Neuroscience, 2003, 23, 5219-5226.	3.8	225
78	Time Course of the Development of Alzheimer-like Pathology in the Doubly Transgenic PS1+APP Mouse. Experimental Neurology, 2002, 173, 183-195.	4.1	230
79	Microglial Activation and Î²-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice. Journal of Neuroscience, 2002, 22, 2246-2254.	3.8	359
80	Neuropathology of Mice Carrying Mutant APPswe and/or PS1M146L Transgenes: Alterations in the p75NTR Cholinergic Basal Forebrain Septohippocampal Pathway. Experimental Neurology, 2001, 170, 227-243.	4.1	82
81	Correlation between cognitive deficits and AÎ² deposits in transgenic APP+PS1 mice. Neurobiology of Aging, 2001, 22, 377-385.	3.2	176
82	Intrahippocampal LPS injections reduce AÃŽÂ² load in APP+PS1 transgenic mice. Neurobiology of Aging, 2001, 22, 1007-1012.	3.2	231
83	Behavioral Assessment of Alzheimer's Transgenic Mice Following Long-Term AÎ² Vaccination: Task Specificity and Correlations between AÎ² Deposition and Spatial Memory. DNA and Cell Biology, 2001, 20, 737-744.	2.0	113
84	Î±-1-Antichymotrypsin Promotes Î²-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 1444-1451.	3.8	134
85	Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Research, 2001, 891, 42-53.	2.3	313
86	Duration and Specificity of Humoral Immune Responses in Mice Vaccinated with the Alzheimer's Disease-Associated Î²-Amyloid 1-42 Peptide. DNA and Cell Biology, 2001, 20, 723-729.	2.0	43
87	Number of AÎ² Inoculations in APP+PS1 Transgenic Mice Influences Antibody Titers, Microglial Activation, and Congophilic Plaque Levels. DNA and Cell Biology, 2001, 20, 731-736.	2.0	90
88	AÎ² peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 2000, 408, 982-985.	36.2	1,513
89	AÎ² and perlecan in rat brain: glial activation, gradual clearance and limited neurotoxicity. Mechanisms of Ageing and Development, 2000, 112, 135-152.	4.6	16
90	Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behavior Genetics, 1999, 29, 177-185.	2.0	323

#	Article	IF	Citations
91	Mice Transgenic for a Human Amyloid Precursor Protein Promoter-lacZ Reporter Construct: Appropriate Cell-Type Expression, But Not Regulation in Brain. Journal of Molecular Neuroscience, 1999, 13, 111-120.	2.4	4
92	Oral Versus Transdermal Selegiline Antidepressant-Like Activity in Rats. Pharmacology Biochemistry and Behavior, 1999, 63, 501-506.	2.8	36
93	Rats receiving systemic 3-nitropropionic acid demonstrate impairment of memory in Morris water maze. Cognitive, Affective and Behavioral Neuroscience, 1999, 27, 561-566.	1.4	11
94	Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine, 1998, 4, 97-100.	30.1	1,295
95	Impaired spatial navigation learning in transgenic mice over-expressing heme oxygenase-1. Brain Research, 1998, 808, 110-112.	2.3	13
96	Regional and Cellular Localization of Presenilin-2 RNA in Rat and Human Brain. Experimental Neurology, 1997, 145, 555-564.	4.1	13
97	Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. Journal of Comparative Neurology, 1997, 388, 106-119.	2.0	94
98	Increased amyloid-Î²42(43) in brains of mice expressing mutant presenilin 1. Nature, 1996, 383, 710-713.	36.2	1,488
99	Ontogeny of glycerol phosphate dehydrogenasepositive oligodendrocytes in rat brain. Impaired differentiation of oligodendrocytes in the myelin deficient mutant rat. International Journal of Developmental Neuroscience, 1992, 10, 243-253.	1.6	11
100	New approaches to the study of central nervous system function. Immune-nervous system interactions and cell culture. Neurobiology of Aging, 1988, 9, 763-765.	3.2	1
101	Pituitary and Hypothalamic Glucose-6-Phosphate Dehydrogenase: Effects of Estradiol and Age in C57BL/6J Mice*. Endocrinology, 1988, 122, 726-733.	2.8	4
102	Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging. Neurobiology of Aging, 1987, 8, 195-201.	3.2	81
103	Genotypic influences on pituitary responsiveness to haloperidol in mice. Psychoneuroendocrinology, 1987, 12, 211-218.	2.8	2
104	Spontaneous tumors in aging female mice are more prevalent in the lateral pituitary zones. Neurobiology of Aging, 1987, 8, 67-70.	3.2	7
105	Effective Oral Administration of 17Î²-Estradiol to Female C57BL/6J Mice through the Drinking Water1. Biology of Reproduction, 1986, 35, 1088-1095.	2.6	47
106	Topochemical localization of choline acetyltransferase and acetylcholinesterase in mouse brain. Brain Research, 1984, 308, 364-368.	2.3	17